No Picture
News

Halozyme Provides 2019 Pipeline Update And Financial Guidance At 37th Annual JP Morgan Healthcare Conference

– Anticipated ENHANZE® Partner Progress in 2019 Includes One FDA Approval, New Regulatory Submissions and a New Phase 3 Initiation- Completed Enrollment in Phase 3 Metastatic Pancreas Cancer Study with Data Projected in Second Half of 2019

SAN DIEGO,… […]

No Picture
News

In Promise of True Liquid Biopsy for Cancer, Chip Company BioFluidica® Awarded $1.7 Million by National Cancer Institute/National Institutes of Health for Clinical Trial in Children with Acute Lymphoblastic Leukemia

SAN DIEGO, Jan. 7, 2019 /PRNewswire/ — BioFluidica, a privately held cancer diagnostics company, has been awarded an SBIR Phase II National Institutes of Health grant of $1.7 million for a clinical trial in support of “Increased sensitivity of mini… […]

No Picture
News

Stemedica Cell Technologies Reports Positive Data in Phase I/IIa Study of Allogeneic Stem Cells for Ischemic Stroke

– itMSCs were safe and well tolerated in the study — Results of the study are supportive of advancing clinical program — Plans are underway to conduct Phase IIb trial following consultation with the FDA –

SAN DIEGO, Jan. 7, 2019 /PRNewswire/ — Ste… […]

No Picture
News

Mirati Announces Clinical Collaboration With Bristol-Myers Squibb For The Planned Phase 3 Trial In Non-Small Cell Lung Cancer To Evaluate Sitravatinib In Combination With Nivolumab (OPDIVO®)

SAN DIEGO, Jan. 7, 2019 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX) a clinical-stage targeted oncology company, today announced a clinical collaboration with Bristol-Myers Squibb Company to evaluate the combination of sitravatinib and n… […]

No Picture
News

Genomic Health Marks More than 1 Million Patients Worldwide Who Have Benefited from Oncotype DX Testing in Personalizing Cancer Treatment Decisions to Improve Outcomes

Pioneering Precision Medicine While Saving Healthcare Costs

REDWOOD CITY, Calif., Jan. 7, 2019 /PRNewswire/ — Genomic Health, Inc. (NASDAQ: GHDX) today announced that, in collaboration with physicians around the world, it has delivered more than 1 m… […]

No Picture
News

Regulus Announces Clinical Candidate Nomination for the Treatment of Glioblastoma Multiforme

LA JOLLA, Calif., Jan. 7, 2019 /PRNewswire/ — Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the nomination of RGLS5579 as … […]